Tom Fenton moves from local AI concepts to hands-on tools for matching LLMs to hardware, running local chatbots with Ollama and benchmarking AI performance.
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...